Pilot study of fluvoxamine treatment for climacteric symptoms in Japanese women

详细信息    查看全文

• 作者：Akira Oishi (1)
  Yoshiko Mochizuki (1)
  Reiko Otsu (1)
  Noriyuki Inaba (1)
  
• 刊名：BioPsychoSocial Medicine
• 出版年：2007
• 出版时间：December 2007
• 年：2007
• 卷：1
• 期：1
• 全文大小：170KB
• 参考文献：1. Greendale GA, Lee NP, Arriola ER: The menopause. / Lancet 1999, 353:571鈥?80. CrossRef
  2. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. / JAMA 2002, 88:321鈥?33.
  3. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in post menopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. / JAMA 2004, 291:1701鈥?712. CrossRef
  4. Gonzales GF, Carillo C: Blood serotonin levels in postmenopausal women ; effect of age and serum oestradiol therapy levels. / Maturitas 1993, 17:23鈥?9. CrossRef
  5. Loprinzi CL, Sloan JA, Perez EA, Quella SK, Stella PJ, Mailliard JA, Halyard MY, Pruthi S, Novothy PJ, Rummans TA: Phase III evaluation of fluoxetine for treatment of hot flashes. / J Clin Oncol 2002, 20:1578鈥?583. CrossRef
  6. Stearns V, Isaacs C, Rowland J, Crawford J, Ellis MJ, Kramer R, Lawrence W, Hanfelt JJ, Hayes DF: A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil) in controlling hot flashes in breast cancer survivors. / ANN ONCOL 2000, 11:17鈥?2. CrossRef
  7. Stearns V, Beebe KL, Iyengar M, Dube E: Paroxetine controlled release in the treatment of menopausal hot flashes. / JAMA 2003, 289:2827鈥?834. CrossRef
  8. Suri R, Burt VK, Altshuler LL, Zuckerbrow-miller J, Fairbanks L: Fluvoxamine for postpartum depression. / Am J Psychiatry 2001, 158:1739鈥?740. CrossRef
  9. Zung WWK: A self-rating depression scale. / Arch Gen Psychiatry 1965, 12:63鈥?0.
  10. Rockliff BW: A brief self-rating questionnaire for depression (SRQ-D). / Psychosomatics 1969, 10:236鈥?43.
  11. Blumenthal SJ: Women and depression. / J Womens Health Gend Based Med 1994, 3:467鈥?79.
  12. Holinka CF, Pickar JH: Clinical studies in hormone replacement therapy: Treatment of the postmenopausal woman. / 2 Edition / (Edited by: Lobo RA). Philadelphia: Lippincott Williams & Wilkins 2002, 629鈥?37.
  13. Kronenberg F: Hot flashes: phenomenology, quality of life, and search for treatment options. / Exp Gerontol 1994, 29:319鈥?36. CrossRef
  14. Sherwin BB: The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. / J Clin Endocrinol Metab 1991, 72:336鈥?43. CrossRef
  15. Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, LaVasseur BI, Barton DL, Novotny PJ, Dakhil SR, Rodger K, Rummans TA, Christensen BJ: Venlafaxine in management of hot flashes in survivors of breast cancer: a randomized controlled trial. / Lancet 2000, 356:2059鈥?063. CrossRef
  16. Ware MR: Fluvoxamine: A review of the controlled trial in depression. / J Clin Psychiatry 1997,58(Suppl 5):15鈥?3.
  17. Classen V: Review of the animal pharmacology and pharmacokinetics of fluvoxamine. / Br J Clin Pharmacol 1983,15(Suppl 3):49s-55s.
  18. Fuyuki T, Ohta H, Makita K, Takamatsu K, Horiguchi F, Nozawa S: Hormone replacement therapy on climacteric symptoms. / Obstet Gynecol Ther 1998,76(suppl):158鈥?65.
  19. Pan B, Kato Y, Sengoku K, Takuma N, Niizeki N, Ishikawa M: Treatment of climacteric symptoms with herbal formulas of traditional Chinese medicine. / Gynecol Obstet Invest 2004, 57:144鈥?48. CrossRef
  20. Weitzner MA, Moncello J, MSN , ARNP , Jacobsen PB, Minton S: A pilot trial of Paroxetine for the treatment of hot flashes and associated symptoms in women with breast cancer. / J Pain Symptom Manag 2002, 23:337鈥?45. CrossRef
  21. Sherwin BB, Suranyi-Cadotte BE: Up-regulatory effect of estrogen on platelet ³ H-imipramine binding sites in surgically menopausal women. / Biol Psychiatry 1990, 28:339鈥?48. CrossRef
  22. Backstrom T: Symptoms related to the menopause and sex steroid treatments. / Ciba Found Symp 1995, 191:171鈥?80.
  23. Stahl SM: Essential psychopharmacology: neuroscientific basis and practical applications. Cambridge UK: Cambridge University Press 1996.
  
• 作者单位：Akira Oishi (1)
  Yoshiko Mochizuki (1)
  Reiko Otsu (1)
  Noriyuki Inaba (1)
  
  1. Department of Obstetrics and Gynecology, Dokkyo University School of Medicine, Mibu, Tochigi, Japan
  

文摘

Background Selective serotonin-reuptake inhibitors (SSRIs) are commonly prescribed for the treatment of depression and can be used as nonhormonal alternatives to manage hot flashes for women with a history of breast cancer and unable to take hormone replacement therapy. There are, however, few reports on the efficacy of SSRIs for the treatment of natural postmenopausal climacteric symptoms. In this pilot study, we evaluate the SSRI, fluvoxamine, for controlling climacteric symptoms and vasomotor symptoms, in particular. Methods Twenty-two patients were enrolled from our hospital. All were orally administered fluvoxamine (50 mg daily). Climacteric and depressive symptoms were assessed using simple menopausal index (SMI) and self-rating questionnaire for depression (SRQ-D), respectively, at baseline, and at 2 and 6 weeks post-treatment. Results Six weeks following drug administration, neither the SRQ-D nor SMI scores significantly decreased compared to baseline. The mean levels of vasomotor symptoms and mental symptoms decreased significantly following fluvoxamine administration, while skeletal muscle symptom scores did not. Conclusion We were able to demonstrate that fluvoxamine was effective in treating not only depressive moods in climacteric symptoms but also the associated vasomotor symptoms. There are several limitations to this preliminary study. Future controlled studies are needed to further evaluate the efficacy of fluvoxamine for climacteric disturbances.